One day surgery in the treatment of benign prostatic enlargement with thulium laser: A single institution experience.
10.4111/kju.2015.56.5.365
- Author:
Luca CARMIGNANI
1
;
Alberto MACCHI
;
Dario RATTI
;
Elisabetta FINKELBERG
;
Stefano CASELLATO
;
Serena MARUCCIA
;
Carlo MARENGHI
;
Stefano Carlo Maria PICOZZI
Author Information
1. Department of Urology, IRCCS Policlinico San Donato, Milan, Italy. stepico@tin.it
- Publication Type:Original Article ; Video-Audio Media
- Keywords:
Lasers;
Prostate;
Prostatic hyperplasia;
Thulium
- MeSH:
Aged;
Ambulatory Surgical Procedures;
Humans;
Laser Therapy/adverse effects/*instrumentation;
Lasers, Solid-State/*therapeutic use;
Length of Stay;
Male;
Middle Aged;
Operative Time;
Prospective Studies;
Prostate/*surgery;
Prostatic Hyperplasia/*surgery;
Thulium/*therapeutic use;
Transurethral Resection of Prostate;
Treatment Outcome
- From:Korean Journal of Urology
2015;56(5):365-369
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Various articles have previously addressed the introduction of new surgical laser therapies for an enlarged prostate gland causing obstructive symptoms. The objective of this study was to report the feasibility of performing the thulium laser vapo-enucleation of the prostate (ThuVEP) procedure for benign prostatic obstruction in a 1-day surgery. MATERIALS AND METHODS: From September 2011 to September 2013, we conducted a prospective study on patients who underwent ThuVEP in a 1-day surgery. The primary outcomes measured perioperatively included operative time, resected tissue weight, hemoglobin decrease, transfusion rate, postoperative irrigation and catheterization time, and postoperative hospital stay. Also, the preoperative and postoperative International Prostate Symptom Score (IPSS) and results of uroflowmetry performed on the 7th and 30th postoperative days were recorded. All perioperative and postoperative complications were monitored. RESULTS: A total of 53 patients underwent the surgical treatment in a 1-day surgery. Seven patients continued antiaggregant therapy with aspirin. Mean preoperative prostatic adenoma volume was 56.6 mL. Mean operative time was 71 minutes. The average catheter time was 14.8 hours. The peak urinary flow rate on day 7 improved from 9.3 to 17.42 mL/s (p<0.001) and the IPSS improved from 18 to 10.2 (p<0.01). Patients were routinely discharged on the day of catheter removal. No complications were recorded. CONCLUSIONS: ThuVEP can be safely conducted as a 1-day surgical procedure. This strategy results in cost savings. ThuVEP shows good standardized outcomes with respect to improvement in flow parameters and length of bladder catheterization.
